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Abdominal aortic aneurysm (AAA) is an important cause of mortality in older adults. Most AAAs are 79 
asymptomatic and screening programs have been introduced to identify AAAs at an early stage in some 80 
countries. There is currently no accepted therapy for early stage or small AAAs, which are frequently 81 
identified by such programs. In this review we discuss work underway to identify targets for medical 82 
treatments to limit progression of small AAAs. Specifically we discuss studies, which have examined 83 
the potential of targeting inflammation, proteolysis, the renin angiotensin system, the coagulation 84 
system and sex hormones on AAA pathogenesis. As yet none of the treatment targets have translated 85 






















1. Introduction 107 
Abdominal aortic aneurysm (AAA) is a common degenerative disease of the aorta particularly 108 
affecting people aged > 65 years.(1-4) AAA is usually asymptomatic unless rupture occurs which is 109 
frequently fatal.(1, 2) AAA is also associated with a higher risk of other major cardiovascular 110 
events.(5) It has been reported for example, that over 45% of patients with small AAAs die secondary 111 
to myocardial infarction and stroke.(6) The primary focus of treatment is to prevent AAA rupture since 112 
this is the main recognised complication of this problem. Aortic dilatation is usually progressive and 113 
there is an absence of effective medications to limit aneurysm progression.(5, 7) Current guidelines 114 
indicate that patients with large AAAs (>50-55mm) should be considered for endovascular or open 115 
surgical repair.(7, 8) In patients with smaller AAAs, where surgical intervention is not recommended, 116 
regular clinical review and ultrasound monitoring of aortic diameter is recommended because of the 117 
lack of approved effective non-surgical interventional options for the disease.(9) Up to 60% of small 118 
AAAs undergoing monitoring expand to a size requiring surgical repair.(5, 10, 11) The development of 119 
medications that can effectively limit the number of patients requiring AAA surgery would have 120 
potential patient and cost benefits. In this article we outline current progress in developing 121 
pharmacotherapy for AAA. 122 
 123 
2. AAA Pathology 124 
AAA is generally accepted to be a complex disease due to aberrant interactions between environmental 125 
risk factors and genetic predisposition which exacerbate the normal ageing processes.(5) Once 126 
initiated, AAA is characterised by a number of key features. These include significant remodelling and 127 
degradation of the extracellular matrix (ECM) by proteolytic enzymes such as matrix 128 
metalloproteinases (MMPs),(12, 13) significant reductions in vascular smooth muscles (VSMC) 129 
density(14, 15) and chronic inflammation denoted by invasion of the tunica media by macrophages and 130 
mononuclear lymphocytes.(16-21) Intraluminal thrombus (ILT) and vascular calcifications are usually 131 
associated with AAA and have been implicated in AAA formation,(22, 23) progression,(24-27) and 132 
rupture.(18, 27-31) Localised hypoxia and increased wall stress have been reported within areas of the 133 
aorta covered by ILT.(32) Neutrophil gelatinase associated lipocalin (NGAL) found in all layers of 134 
ILT,(30)is reported to prevent MMP-9 inactivation,(33) and the NGAL-MMP-9 complex has been 135 
suggested to encourage the proteolytic degradation of the ECM.(30) ILT promotes the migration of 136 
inflammatory cells such as neutrophils(30), macrophages and T-lymphocytes,(18) which can 137 
potentially promote VSMC apoptosis and thinning of the aortic wall.(18) This presence of effector 138 
immune cells and their products together with observed immunoreactivity of IgG purified from AAA 139 
tissue to ECM proteins suggests an autoimmune aspect to AAA formation.(5, 34, 35) However, once 140 
triggered, alterations within the aortic wall most likely continue in a vicious cycle ending in 141 
progressive loss of normal ECM configuration and phenotypic modulation of VSMC.(36) 142 
Because of the difficulty associated with obtaining human AAA tissue biopsies (most patients undergo 143 
endovascular aneurysm repair rather than open surgery),(37) and the fact that these biopsies are usually 144 
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obtained at the end-stage of disease progression, much of the knowledge gained about AAA has been 145 
obtained from animal models.(38, 39) In some cases, investigations have been supplemented by using 146 
explant culture of human samples.(1, 40-42) The animal models and the ex-vivo studies have been used 147 
extensively to screen putative therapeutic targets for AAA.(1, 41, 43-46) 148 
 149 
3. Putative therapeutic strategies 150 
 A number of therapeutic strategies for AAA have been researched in both pre-clinical and clinical 151 
studies in the past decade (Figure 1). These include investigations into pathways implicated in AAA 152 
pathogenesis such as the renin-angiotensin system (RAS), inflammatory pathways, intracellular 153 
signalling pathways, and agents known to affect some or all of the aforementioned processes such as 154 
sex hormones, cholesterol lowering agents, protease inhibitors, immune cell modulators and anti-155 
platelet therapy. 156 
 157 
      3.1 The RAS 158 
The RAS is an important regulator of cardiovascular homeostasis.(47) The RAS has been implicated in 159 
ECM remodelling,(36) and inflammatory pathways involved in AAA formation in animal models.(38, 160 
47-49) The key peptide in the RAS is the octapeptide angiotensin II (Ang II), which is known to exert 161 
its proinflammatory effects by inducing the expression of several chemokines and adhesion 162 
molecules.(41, 50, 51) Continuous infusion of Ang II has been widely reported to result in AAA in the 163 
pro-atherosclerotic hyperlipidaemic apolipoprotein E deficient (ApoE-/-) mouse.(48, 50, 52) In addition, 164 
a number of studies have implicated the RAS in human AAA pathogenesis.(53-56) The activities of the 165 
Ang II forming enzymes, angiotensin converting enzyme (ACE) and chymase have been reported to be 166 
upregulated in the aneurysmal aorta.(55, 56) Therefore, there has been a lot of interest in targeting the 167 
RAS pathway as a putative treatment for AAA. Consequently, ACE inhibitors and Ang II receptor 168 
blockers (ARB) have been investigated in several studies as putative pharmacological therapies for 169 
AAA. These drugs are already established as being beneficial in treating hypertension and heart 170 
failure.(57, 58) 171 
 172 
Three ACE inhibitors (enalapril, captopril and Lisinopril) but not the angiotensin receptor blocker, 173 
losartan were reported to inhibit AAA development in the elastase infused rat model of AAA.(59) 174 
These medications were shown to attenuate aortic media elastin degradation independent of their effect 175 
on blood pressure and without diminishing the elastase-induced inflammatory response.(59) In 176 
contrast, Daugherty et al. demonstrated that losartan inhibited Ang II-induced AAA in ApoE-/- 177 
mice.(60) The discrepant effect of losartan on AAA formation suggests that ARBs exert different 178 
effects depending on the animal model. However, Fujiwara and colleagues reported that another ARB, 179 
valsartan inhibited AAA development in the elastase-induced AAA rat model independent of its 180 
antihypertensive effect.(61) They showed that valsartan inhibited nuclear factor-κB (NF-κB) 181 
activation, macrophage infiltration, and MMP-2 and -9 expression.(61) Recently, employing the Ang 182 
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II-induced ApoE-/- mouse model of AAA, we found that aliskiren, the direct renin inhibitor,(62) 183 
significantly inhibited AAA progression and reduced aortic arch atherosclerosis.(43) Aliskiren was 184 
also found to reduce aortic pro-renin receptor expression, mitogen-activated protein kinase activity, 185 
and aortic inflammation.(43) 186 
 187 
Human studies are also contradictory. For example, in a population based case-control study, ACE 188 
inhibitor but not ARB prescription were reported to be significantly associated with a decreased risk of 189 
AAA rupture.(63) Contrary to this, Sweeting and colleagues reported an increased risk of aortic 190 
expansion in patients receiving ACE inhibitors in a prospective cohort study of patients enrolled in the 191 
UK small aneurysm trial.(64) Thus, there is conflicting evidence on the potential beneficial or 192 
detrimental effects of targeting the RAS for AAA therapy. There are a number of on-going clinical 193 
trials examining the effect of blocking the RAS on small AAA progression.(37) Examples of animal and 194 
human association studies linking the RAS with AAA are shown in Table 1.  195 
 196 
3.2 Sex hormones  197 
Until recently, it has been widely accepted that the female sex confers some form of protection from 198 
AAA.(65, 66) The predilection of AAA for the males and emerging data linking estrogen and estrogen 199 
receptor modulation with reduced inflammation in women,(67) has resulted in a number of studies 200 
investigating the effect of gonadal hormones on AAA pathogenesis (Table 2). For example, Ailawadi 201 
et al. reported that 17β-estradiol inhibited AAA development in an elastase rat model associated with 202 
decreased aortic medial macrophage infiltration, and lower MMP-9 concentrations.(68) Martin-203 
McNulty and colleagues demonstrated a reduction in AAA size in mice receiving 17β-estradiol 204 
characterised by decreased expression of monocyte chemoattractant protein-1 (MCP-1), and NF-κB 205 
activity in the Ang II-infused mouse model of AAA.(69) In a separate study, Grigoryants et al. 206 
demonstrated that the selective estrogen receptor modulator, tamoxifen significantly reduced AAA, 207 
MMP-9 expression and inflammatory neutrophil infiltration in an elastase-induced AAA rat model.(70) 208 
This effect was partially abrogated by a catalase inhibitor suggesting that the superoxide pathway was 209 
involved. The effect of gonadal hormones on AAA development in animal models is not completely 210 
consistent. Henriques and colleagues reported that ovariectomy in female mice did not result in 211 
increased AAA formation whereas orchidectomy reduced aneurysm size in male mice in the Ang II-212 
induced model of AAA.(71) Collectively, these data suggest that gonadal hormones may play a role in 213 
AAA formation; however more work is needed to clarify a safe and effective target for AAA therapy. 214 
 215 
3.3 Inflammatory pathways 216 
AAA is regarded as the consequence of a chronic inflammatory process due to the intense 217 
inflammation seen within AAA wall biopsies.(1, 44, 72, 73) A number of proinflammatory factors, 218 
such as reactive oxygen species (ROS), interleukin-6 (IL-6), MCP-1, and tumor necrosis factor-α 219 
(TNF-α) have been implicated in AAA pathogenesis.(74, 75) In addition, prostaglandins, a group of 220 
lipid autacoids derived from arachidonic acid and cyclooxygenase have been implicated in aortic 221 
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medial degradation through the production of MMPs.(76, 77) Evidence suggests that both 222 
prostaglandin E2 (PGE2) and cyclooxygenase-2 (COX-2) are significantly upregulated in aneurysmal 223 
tissue and encourages VSMC apoptosis.(78-81) Consequently, medication designed to inhibit the 224 
inflammatory process has been studied as a means of deterring AAA expansion.  225 
 226 
A number of studies examining the therapeutic potential of cyclooxygenase inhibitors in limiting AAA 227 
development have been described. For example, the selective COX-2 inhibitor celecoxib, a 228 
sulfonamide nonsteroidal anti-inflammatory drug (NSAID) was shown to decrease the incidence and 229 
severity of AAA in the Ang II-induced mouse model.(45) In addition, Gitlin et al. demonstrated that 230 
COX-2 deficient mice infused with Ang II failed to develop AAA.(82) These data suggest that COX-2 231 
may serve as a putative pharmacotherapeutic target for AAA.  232 
 233 
Indomethacin, another NSAID, have been demonstrated in two separate studies utilising an elastase-234 
induced rat model of AAA to significantly inhibit PGE2 and MMP-9 expression thereby maintaining 235 
elastin integrity and decreasing AAA expansion with no effect on the inflammatory infiltrate.(83, 84) 236 
Furthermore, Walton et al. demonstrated a significant reduction in AAA growth rate in patients 237 
receiving NSAIDs in a small case-control study involving 15 patients receiving NSAIDs and 63 238 
patients without NSAIDs.(81) Concerns regarding the safety of cyclooxygenase inhibitors particularly 239 
their association with increased incidence of major cardiovascular events including myocardial 240 
infarction and stroke,(85, 86) may deter further investigation of these agents as potential therapeutic 241 
targets for AAA. 242 
 243 
A number of agents modulating ROS production have been investigated including vitamin E (α-244 
Tocopherol), a lipid-soluble antioxidant (reviewed in detail by Singh et al.).(87) Vitamin E is reported 245 
to inhibit the release of ROS, attenuate proinflammatory cytokine and chemokine release, and regress 246 
the expression of vascular cell adhesion molecule-1 (VCAM-1), E-selectin, and intercellular adhesion 247 
molecule-1 (ICAM-1). Vitamin E is also reported to inhibit cyclooxygenase expression by monocytes 248 
thereby abrogating PGE2 synthesis.(87) It has been reported that vitamin E inhibits AAA formation in 249 
two different rodent models of AAA.(88, 89) Gavrila et al. reported reduced levels of ROS and aortic 250 
macrophage infiltration along with reduction in maximum AAA diameter and incidence of rupture in 251 
mice receiving vitamin E in a study employing the Ang II-induced mouse model of AAA.(89) 252 
Similarly, Nakahashi and colleagues reported that rats receiving vitamin E had significantly decreased 253 
AAA expansion rate compared to controls in the elastase-induced rat model of AAA.(88) However, a 254 
randomised double-blind placebo-controlled trial by Tornwall et al. suggested that vitamin E and β-255 
carotene supplements did not reduce the incidence of AAA diagnosis or rupture in patients.(90)  256 
 257 
A number of immune suppressants have been investigated as potential therapies for AAA. For 258 
example, rapamycin (sirolimus) an mTOR inhibitor used extensively in kidney transplants and in 259 
vascular stents to avert intimal hyperplasia,(91, 92) was shown to significantly reduce AAA 260 
development in the elastase-induced rat model of AAA via inhibition of MMP-9 and NF-κB 261 
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expression.(93) We also recently demonstrated that the rapamycin rapalog everolimus, restricts AAA 262 
development in the Ang II-induced ApoE-/- mouse model by suppressing the development and 263 
migration of bone marrow derived chemokine receptor 2 expressing monocytes.(44) In vitro, we found 264 
that everolimus abrogated Ang II-stimulated production of interferon gamma (IFN-γ) in ApoE-/- mice 265 
bone marrow. Furthermore, the potent immunosuppressive drugs, methylprednisolone and cyclosporine 266 
were demonstrated to inhibit AAA formation in an elastase-induced rat model of AAA.(94) The major 267 
difference between the cyclosporine treated and methylprednisolone treated groups was the presence of 268 
moderate oedema in the cyclosporine treated animals. However, both groups exhibited intact elastin 269 
lamellae.(94) Considering the generalised systemic effects of immune suppressants and the difficulty in 270 
achieving a balance between the beneficial and the detrimental effects of these medications, it is 271 
unclear whether this form of treatment would be appropriate for older patients at risk of cancer and 272 
serious infective complications. 273 
  274 
Curcumin (diferuloylmethane), a natural phenol found in the dietary spice tumeric has been reported to 275 
exert anti-inflammatory effects via inhibition of the production of ROS and nitric oxide synthase 276 
enzymes.(95-97) Preliminary studies by Parodi et al. employing an elastase-induced mouse model of 277 
AAA revealed that curcumin decreased aortic tissue concentrations of MCP-1, IL-6, NF-κB, 278 
interleukin-1β (IL-1β) and MMP-9. AAA development in the mice that received oral administration of 279 
curcumin was reduced.(98) Given the potential carcinogenic effects ascribed to cucurmin,(99) caution 280 
is advised in furthering this agent as a potential therapy for AAA. Examples of animal and human 281 
association studies investigating the therapeutic effect of targeting inflammatory pathways are outlined 282 
in Table 3.  283 
 284 
 285 
3.4 Cholesterol lowering agents 286 
Statins are a class of lipid-lowering drugs, also known as 3-hydroxyl-3-methylglutaryl coenzyme A 287 
(HMG-CoA) reductase inhibitors with putative beneficial pleiotropic effects including antioxidant, 288 
anti-inflammatory and anti-proteolytic effects which may be beneficial in various cardiovascular 289 
diseases.(100-104) Statins have also been shown to improve stability of atherosclerotic plaque, inhibit 290 
thrombogenesis, and improve endothelial function.(105, 106) Despite the lack of convincing 291 
association between serum cholesterol and AAA expansion rate, several data indicate that statin 292 
therapy may inhibit AAA pathogenesis due to the above-mentioned pleiotropic effects (Table 4).(46, 293 
107-113)  294 
 295 
Simvastatin has been reported to inhibit AAA development in a number of rodent studies.(46, 107, 110, 296 
114) For example, Steinmetz et al. demonstrated that simvastatin inhibited AAA formation 297 
independent of serum cholesterol levels in the C57BL/6 wildtype and in hyperlipidaemic ApoE-/- mice 298 
using the elastase-infused mice model of AAA.(107) The authors showed a reduction in MMP-9 299 
expression with a marked increase in tissue inhibitor of metalloproteinase-1 (TIMP-1) expression, 300 
maintenance of elastin integrity, and VSMC preservation but no effect on inflammatory infiltrate 301 
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composition following administration of simvastatin.(107) In support, Kalyanasundaram et al. showed 302 
that simvastatin inhibited AAA formation in an elastase-induced rat model.(110) They also 303 
demonstrated that simvastatin reduced NF-κB and MMP-9 concentrations, and further downregulated 304 
the gene expression of several proinflammatory cytokines and chemokines.(110) In contrast, in a 305 
further study employing the Ang II-induced mouse model of AAA, there was no significant reduction 306 
in AAA diameter following simvastatin administration.(46) Interestingly simvastatin exerted a more 307 
potent effect on intimal atherosclerosis rather than on aortic dilation.(46)  308 
 309 
Cerivastatin a synthetic statin withdrawn from the general circulation in 2001 (due to reports of fatal 310 
rhabdomyolysis),(115) has been reported to decrease MMP-9 concentration  and neutrophil activation 311 
with no effect on TIMP-1 in ex vivo human AAA organ culture.(116) Furthermore, inhibition of 312 
cerivastatin activity abrogated these effects on proteolysis and inflammation. 313 
 314 
Atorvastatin has been reported to prevent AAA development by suppressing macrophage recruitment 315 
via inhibition of MCP-1, MMP-12 and ICAM-1 but not MMP-9 expression in an elastase-induced rat 316 
model of AAA.(113) In a similar experiment, Houdek and colleagues did not find any significant 317 
reduction in AAA formation in mice administered atorvastatin.(117) They did report a noticeable 318 
improvement in elastin integrity and VSMC preservation in the atorvastatin treated group.(117) 319 
Takahashi et al., demonstrated no significant effect of atorvastatin on aortic diameter in an Ang II-320 
induced mouse model of AAA.(118) They did however show that combined therapy with amlodipine, a 321 
calcium channel blocker significantly suppressed aneurysm formation via inhibition of Rho-kinase 322 
activity and elastin degradation.(118) Also, we have previously reported that fenofibrate a peroxisome 323 
proliferator-activated receptor alpha (PPARα) activator used clinically to reduce triglycerides 324 
antagonizes Ang II-induced AAA in low-density lipoprotein receptor-deficient (Ldlr-/-) and ApoE-/- 325 
mice.(48, 119) 326 
 327 
Several human observational investigations report an association between statin treatment and reduced 328 
AAA progression.(108, 109, 111, 120-123) In a prospective study investigating the beneficial effect of 329 
simvastatin in 32 patients, Evans et al., demonstrated a 40% reduction in MMP-9 levels in the AAA 330 
wall in patients randomised to simvastatin compared to placebo prior to open aneurysm repair.(111) 331 
Schweitzer and colleagues reported a reduction in MMP-13, transforming growth factor beta (TGF-β), 332 
but not MMP-9 in 19 patients administered atorvastatin compared to 19 patients not receiving 333 
atorvastatin.(124) Schouten et al. investigated the effect of statins on 150 patients under surveillance 334 
for AAA.(108) They demonstrated a significant reduction in AAA growth rate independent of other 335 
cardiovascular factors in 59 patients receiving statins compared to 91 patients not on statins, after 336 
approximately 3 years median follow-up.(108) In another retrospective study evaluating the effects of 337 
statins on the growth rate of small aneurysm in 211 patients, Karrowni and colleagues demonstrated a 338 
significant association between statins use and reduced AAA expansion.(122) They showed that the 339 
mean growth rate for 75 patients not receiving statins was 3.2 mm per year but 0.9 mm per year for 136 340 
patients on statins.(122)  341 
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Some larger clinical studies, however have failed to confirm an association of statins with reduced 342 
AAA expansion rate.(125, 126) For example, in a multicentre large observational study analysing the 343 
effects of statins on AAA growth in 652 patients undergoing surveillance of small AAAs, we found no 344 
significant association of statins prescription with AAA growth.(126) Patients receiving statins (n=349) 345 
were compared with patients not prescribed statins (n=303). AAA growth were similar in both patient 346 
group,(126) which was in contrast to earlier but smaller studies described above.(108, 111, 122, 123) 347 
This finding was further reinforced by the Tromso study, in which Forsdahl et al. reported follow up of 348 
4000 subjects over seven years.(127) They reported that the subjects receiving statins were more likely 349 
to develop AAAs. It is possible that statins prescription simply identified a sub-set of individuals with 350 
risk factors putting them at excess likelihood of developing an AAA, although the investigators did 351 
attempt to adjust for potential confounding factors.(127) A large number of studies have suggested 352 
improved perioperative and postoperative longer-term outcomes in patients prescribed statins prior to 353 
aneurysm repair.(101, 128-136) Recent European and American guidelines suggest that patients with 354 
large AAAs being considered for intervention should receive statins because of considerable data 355 
linking statins with reduced cardiovascular events.(137, 138) A randomised trial to examine the benefit 356 
of statins in reducing AAA expansion would therefore be far more straightforward to undertake. 357 
  358 
3.5 NF-κB, Rho/Rho-kinase and c-Jun N-terminal kinase inhibitors 359 
The pharmacological modulation of signalling pathways including c-Jun N-terminal kinase (JNK), NF-360 
κB, Rho/Rho-kinase has been suggested as an effective therapy for AAA in rodent studies (Table 361 
5).(139-143) Wang et al. reported that Ang II-infused ApoE-/- mice given fasudil [5-(1,4-diazepane-1-362 
sulfonyl) isoquinoline], a Rho-kinase inhibitor in their drinking water had both a reduced incidence and 363 
severity of Ang II-induced AAA. Fasudil was shown to reduce proteolysis by MMP-2 and MMP-9 364 
with consequent decrease in VSMC apoptosis and AAA formation.(143) 365 
 366 
In a different group of studies the therapeutic potential of JNK, an important regulator of activator 367 
protein 1 (AP-1, which is a key transcriptional regulator of MMP-9), has been described.(139, 141, 368 
144) In calcium chloride-induced and Ang II-induced mouse models of AAA, Yoshimura et al. 369 
demonstrated that SP600125 (1,9-pyrazoloanthrone), a specific JNK inhibitor, completely abrogated 370 
the development of AAA by decreasing MMP-9 expression, macrophage infiltration and improving 371 
elastin integrity. SP600125 was also shown to reduce AAA size after experimental induction of AAA 372 
with improved elastin integrity by upregulating lysyl oxidase and prolyl-4-hydroxylase, enzymes 373 
critical for the crosslinking and stable maturation of elastin and collagen.(139) SP600125 was also 374 
shown to suppress the secretion of MMP-2 and MMP-9 in the walls of human AAA explants in 375 
culture.(141, 145) 376 
  377 
A number of studies have suggested that medication-targeting NF-κB may be useful in treating 378 
AAA.(142, 143, 146, 147) NF-κB is a well-researched transcription factor that regulates numerous 379 
genes implicated in inflammation and immune response.(148-155) A number of proinflammatory 380 
cytokines (e.g TNF-α, IL-1, IL-6, IL-2), chemokines (e.g. IL-8),(148-150) adhesion molecules (e.g. 381 
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ICAM-1, VCAM-1), (151, 152) and proteolytic enzymes (e.g. MMPs, MMP-1, -2 and -3, -9),(153, 382 
154) (155, 156) are directly regulated by NF-κB. NF-κB upregulation has been shown to promote 383 
experimental AAA in rats.(146) A recent study in an elastase-induced mouse model of AAA suggested 384 
that blocking NF-κB activity with pyrrolidine dithiocarbamate (PDTC) significantly reduced the 385 
incidence of AAA and AAA size via inhibition of IL-1β, IL-6 and MMP-9 expression.(142) 386 
 387 
3.6 Protease inhibitors 388 
AAA pathogenesis including formation, growth and eventual rupture is intricately linked with 389 
connective tissue destruction especially loss of aortic media and adventitia elastin.(157-161) 390 
Proteolytic enzymes such as MMP-9 and -2 have been implicated in ECM degradation resulting in 391 
aneurysm formation.(144, 162, 163) Animal based investigations,(164) as well as in vitro studies on 392 
human aortic tissue(157, 160) suggest that proteases including MMPs, cathepsins, and neutrophil 393 
elastase secreted by inflammatory cells and VSMC are involved in the destruction of the aortic wall 394 
and subsequent AAA formation.(157-160) MMPs are Zn2+ and Ca2+ dependent enzymes,(158, 165, 395 
166) and are secreted in an inactive zymogen form.(157) They are then activated by mast cells and 396 
plasmin generated from plasminogen by the action of plasminogen activating factors such as urokinase-397 
type plasminogen activator (uPA) and tissue plasminogen activator (tPA). Physiologically, MMP 398 
activity is strictly regulated by inhibitors such as α2-macroglobullins, α1-antitrypsin and TIMP, which 399 
help to control the connective tissue turnover rate. However, aberrant protease expression can result in 400 
unbalanced MMP activity, and lead to pathological destruction of the aortic media.(157, 167, 168) 401 
MMP-9 (gelatinase B), and MMP-12 (macrophage elastase) are elevated in animal models of AAA as 402 
well as plasma and sera from patients with AAA.(168, 169) MMP-3 (Stromelysin-1) and MMP-7 403 
(matrilysin) are also reported to be increased in aneurysmal tissue.(160) Over expression of the 404 
collagenases MMP-1 (interstitial collagenase) and MMP-13 (collagenase 3) results in interstitial 405 
collagen degradation and promotes AAA formation. Additionally, high levels of MMP-2 (gelatinase 406 
A), are found in small AAAs, which suggests a role for MMP-2 in early aneurysm formation.(170)  407 
 408 
The theory that Chlamydia or similar infections was important in AAA pathogenesis initially drove an 409 
interest in the use of antibiotics in the treatment of AAA.(171) Petrinec et al. initially reported that 410 
blocking the active form of MMP-2 and -9 with the tetracycline derivative, doxycycline suppressed 411 
AAA formation in an elastase-induced rat model of AAA.(172) Kaito and colleagues demonstrated in a 412 
similar model that doxycycline inhibited MMP-9 activity with consequent decrease in AAA 413 
development without affecting MMP-2 activity.(173) Accumulated evidence derived from in vitro, in 414 
vivo and human studies suggested that doxycycline preserved aortic elastin integrity in a dose 415 
dependent manner, reduced MMP-9 activity and AAA growth with no effect on MMP-14, -2 and TIMP 416 
expression.(157, 162, 173-182)  417 
 418 
A study by Franklin et al. suggested that patients who received a bolus of tetracycline prior to elective 419 
aneurysm repair surgery had reduced MMP-9 and MCP-1 expression.(181) In another study, 420 
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preoperative administration of doxycycline was shown to decrease MMP-9 expression and increase 421 
abrogation of pro-MMP-2 activation in the aortic wall.(183) Mosorin et al. initially published a 422 
randomised placebo-controlled trial of doxycycline in 32 patients with small AAAs measuring between 423 
30 and 55 mm.(184) They reported that doxycycline decreased AAA expansion rate in patients 424 
administered doxycycline compared to patients receiving placebo but the difference was not 425 
statistically significant.(184) In a double-blind randomised Phase II clinical trial of 36 patients with 426 
small AAAs, doxycycline was shown to be safe and well tolerated and associated with significant 427 
decrease in plasma MMP-9 levels with no significant effect on AAA expansion.(185) Linderman et al., 428 
reported that doxycycline reduced inflammation in AAA biopsies compared to placebo in a randomised 429 
trial of patients undergoing open AAA repair.(186) In a separate randomised trial in patients after 430 
endovascular AAA repair, Hackmann and colleagues found that doxycycline reduced plasma levels of 431 
MMP-9, which has been suggested as a biomarker of endograft failure.(187) Meijer et al. published the 432 
results of a large multicentre randomised, placebo-controlled, double-blind trial investigating the effect 433 
of doxycycline on 286 patients with small AAAs (mean aortic diameter ~43mm) completed in the 434 
Netherlands recently.(188) They reported that doxycycline administration was associated with 435 
increased AAA growth [4.1 mm, (n=144)] compared to the placebo allocated group [3.3 mm, (n=142)] 436 
after 18 months.(188) Another doxycycline trial is currently ongoing in the USA. Other strategies of 437 
modifying aortic ECM remodeling are also been explored. For example, Allaire et al. demonstrated 438 
that overexpression of TIMP-1 in VSMC significantly reduced AAA development in a rat model of 439 
AAA.(72) Despite encouraging data from pre-clinical studies, targeting ECM proteolysis has as yet not 440 
translated into a clinically useful strategy. Examples of animal and human studies examining the effect 441 
of protease inhibitors on AAA are shown in Table 5.  442 
 443 
 444 
3.7 Immune cell modulators 445 
A defining feature of AAA is inflammation including an extensive infiltration of mononuclear 446 
lymphocytes and macrophages in the AAA wall.(16, 17, 189) It is proposed that these cells release a 447 
cascade of cytokines that activate proteases and thereby degrade the vessel wall. The stimuli that 448 
initiate inflammation in human AAA still remain to be elucidated. Experimental evidence suggests that 449 
elastin and collagen degradation products in the aortic wall promote the recruitment of inflammatory 450 
cells.(17, 190, 191) The marked inflammation and the identification of IgG in AAA tissue which is 451 
reactive to ECM proteins supports the concept that AAA development is an autoimmune 452 
response.(192) A genetic investigation suggested an association between a human leukocyte antigen 453 
(HLA) allele and AAA (HLA-DQA1).(193) Both innate (natural killer/NK cells, mast cells) and 454 
adaptive (cytotoxic lymphocytes) immune effectors are elevated in the circulation of patients with 455 
AAA.(194-197) Helper T-cell type-1 (Th1) and type-2 (Th2) cytokines have been identified in both 456 
human AAA and animal models.(198) Proinflammatory molecules such as IL-6, IFN-γ, TNF-α, IL-8 457 
and MCP-1 have been reported to be upregulated in AAA tissue and to be responsible for ECM 458 
remodelling.(17, 199, 200) Suppression of AAA development has been reported to be associated with 459 
the inhibition of inflammatory cells in rodent models.(196, 201, 202) 460 
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Mast cells have been implicated in AAA pathogenesis. They have been identified in human AAA 461 
biopsies, and mast cell deficient mice were shown to be resistant to experimental AAA.(196, 203) In 462 
both an elastase-induced and calcium chloride-induced mouse models of AAA, disodium cromoglycate 463 
(DSCG), a mast cell stabilizer was shown to significantly inhibit AAA growth by maintaining elastin 464 
architecture and decreasing inflammation whilst C48/80 a mast cell activator was shown to increase 465 
AAA growth.(196) The authors also demonstrated that mast cell deficient mice failed to develop 466 
elastase or calcium chloride induced AAA.(196) Similarly, Tsuruda et al. found that tranilast, a mast 467 
cell degranulation inhibitor attenuated AAA development in rodents.(202) There is considerable 468 
interest in employing mast cell stabilising agents as a therapy for patients with small aneurysms,(53) 469 
and a current randomised trial is examining this approach.  470 
 471 
3.8 Anti-platelet therapy 472 
Most AAAs contain intraluminal thrombus and we had previously reported a close correlation between 473 
thrombus volume and AAA diameter.(204) It has been demonstrated that AAA thrombus is a rich 474 
source of inflammatory cells, proteolytic enzymes and proinflammatory cytokines.(40, 73, 205) We 475 
have also demonstrated that circulating levels of thrombus products are significantly associated with 476 
AAA presence and progression in patients with small AAAs.(206, 207) 477 
 478 
Platelet inhibition has been reported to inhibit AAA formation in rodent models.(205, 208) Tout et al. 479 
demonstrated that abciximab, a platelet aggregation inhibitor reduced both thrombus area and 480 
aneurysmal enlargement in a rat model of AAA.(205) In a similar study, another platelet aggregation 481 
inhibitor, ticagrelor (AZD6140) was shown to reduce elastin degradation and suppress AAA 482 
growth.(208) 483 
 484 
Two association studies have suggested the efficacy of anti-platelet medication in limiting AAA 485 
progression.(209, 210) Karlsson and colleagues reported that the anti-platelet medication, aspirin 486 
(acetylsalicylic acid) was associated with reduced AAA expansion.(209) They also reported that a 487 
combination of aspirin and statins therapy was more powerfully associated with limited AAA 488 
expansion than aspirin or statins alone.(209) In a different study, Lindholt et al. reported that aspirin 489 
prescription was associated with reduced progression of small AAAs.(210) However, more recent and 490 
larger studies have failed to demonstrate any strong association between anti-platelet medication and 491 
AAA expansion.(64, 125, 126) 492 
 493 
4. Conclusion and future directions 494 
Animal and human data suggests that a complex group of mechanisms are involved in AAA 495 
pathogeneses. The last couple of decades have seen a massive increase in research assessing potential 496 
pharmacotherapy for AAA in experimental models. Several agents targeting mechanisms implicated in 497 
AAA pathogenesis including the RAS, proteolytic processes, inflammatory pathways, the immune 498 
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system and intracellular signalling pathways, have been reported to be effective in pre-clinical studies. 499 
It should be noted that the therapeutic manipulation of microRNAs and their target genes have also 500 
been shown to limit experimental AAA progression recently.(211, 212) However, the efficacy of these 501 
agents has not currently been confirmed in large clinical trials. For example, the efficacy of the very 502 
promising tetracycline derivative, doxycycline reported to inhibit AAA progression in many rodent 503 
pre-clinical and clinical studies, has recently come into doubt with the report of no benefit in a large 504 
randomised clinical trial.(188) The difficulty in translating results from animal studies to patients is 505 
likely due to a number of factors. Firstly investigating drug therapy targets in patients with AAA is 506 
complex. These patients are mainly older adults that frequently have co-morbidities, including 507 
coronary heart disease and cancer, precluding the use of medications that may have significant toxic 508 
side effects. Given the co-morbidities of AAA patients, they are often receiving a range of medications 509 
for other indications, which also makes it difficult to effectively test some medications in trials such as 510 
statins, which are already indicated for cardiovascular risk reduction. Secondly the current major 511 
animal models of AAA rely on acute injury to the aortic wall and it remains unclear how well these 512 
models are suited to identifying treatment targets for human AAA. Thirdly the development of targeted 513 
drugs for any medical condition can take a prolonged time and requires significant investment 514 
particularly from pharmaceutical companies. Only recently have drug companies become interested in 515 
this area and therefore a lag in the development of medications is expected. It is also possible due to 516 
the multifactorial nature of AAA that a successful drug will have to target multiple pathways. There are 517 
a growing number of trials of medications in AAA patients and therefore it is expected that one or more 518 
effective medications will be identified in the near future. It is possible that better delivery of 519 
therapeutic agents,(213-215) and a means of monitoring the efficiency of these agents on AAA 520 
progression in blood (e.g. using biomarkers),(216) may help identify effective medications for AAA 521 
patients. Whether the use of animal models is an effective means to identify appropriate agents to limit 522 
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Figure Legend 1191 
 1192 
Figure 1. Current pharmacotherapeutic strategies/agents of relevance for abdominal aortic aneurysm 1193 
(AAA) treatment. The flow chart shows key processes involved in AAA pathogenesis and potential 1194 
therapeutic targets to deter AAA development and progression. ECM= extracellular matrix, VSMC= 1195 
vascular smooth muscle cells, NSAID= non-steroidal anti-inflammatory drugs, ARB= angiotensin II 1196 



















Table 1 Examples of studies assessing the effect of modulating the renin-angiotensin system on AAA 1215 
development, progression and rupture 1216 
 1217 
Type of Study Agent/Medication Design Effect on AAA 
Animal Enalapril, captopril and 
lisinopril 
Elastase/rat(59) Decreased development 
 Losartan Ang II/ ApoE-/-
/mice(60) 
Decreased development 
 Valsartan Elastase/rat(61) Decreased development 
 Aliskiren Ang II/ ApoE-/- 
/mice(43) 
Decreased progression 
    
Human ACEi Case-control(63) Decreased rupture 
 ACEi Cohort(64) Increased risk of 
progression 
 1218 



























Table 2 Examples of animal studies examining the effect modulating sex hormones on AAA 1245 
development and severity 1246 
 1247 
Type of Study Agent/Medication Design Effect on AAA 
Animal 17β-estradiol Elastase/rat(68) Decreased development 
 17β-estradiol Ang II/ ApoE-/- 
/mice(69) 
Decreased size 
 Tamoxifen Elastase/rat(70) Decreased development 
 Ovariectomy Ang II/ ApoE-/- 
/mice(71) 
No effect 



































Table 3 Examples of studies assessing the effect of targeting inflammatory pathways on AAA 1279 
development and progression 1280 
 1281 
Type of Study Agent/Medication Design Effect on AAA 




 COX-2 deficiency Ang II/COX-2-/-
/mice(82) 
Decreased development 
 Indomethacin Elastase/rat(83, 84) Decreased progression and 
risk of rupture 
 Vitamin E Ang II/ ApoE-/- 
/mice(89) 
Decreased progression and 
rupture 
  Elastase/rat(88) Decreased progression 
 Curcumin Elastase/mice(98) Decrease development 
 Rapamycin Elastase/rat(93) Decreased progression 
 Everolimus Ang II/ ApoE-/- 
/mice(44) 
Decreased development 
 Methylprednisolone and 
cyclosporine 
Elastase/rat(94) Decreased development 
    
Human NSAID Case-control(81) Decreased progression 
 Vitamin E and β-
Carotene 
RCT(90) No effect on progression 
 1282 
Ang II= angiotensin II; ApoE-/-= apolipoprotein E deficient: COX-2-/-= cyclooxygenase 2 deficient; 1283 

























Table 4 Examples of studies assessing the effect of cholesterol lowering agents on AAA development 1308 
and progression 1309 
 1310 
Type of Study Agent/Medication Design Effect on AAA 




  Ang II/ ApoE-/-  and Ang 
II/LDLR-/-/mice(46) 
Limited effect 
  Elastase/rat(110) Decreased progression 
 Atorvastatin Elastase/rat(113) Decreased progression 
  Elastase/rat(117) Limited effect on 
progression 
  Ang II/ ApoE-/- 
/mice(118) 
No effect 
 Atorvastatin + 
amlodipine 




 Fenofibrate Ang II/ ApoE-/- 
/mice(48) 
Decreased progression 
  Ang II/ LDLR-/- 
/mice(119) 
Decreased progression 
    
    
Human Statin Retrospective(108) Decreased progression 
  Retrospective(122) Decreased progression 
  Cohort(126) No effect 
  Prospective(127) Potentially increased 
development 
 1311 
Ang II= angiotensin II; ApoE-/-= apolipoprotein E deficient: C57Bl6= C57 black 6; LDLR-/-= low 1312 




















Table 5 Examples of studies assessing the effect of targeting signalling pathways and proteases on 1332 
AAA development and progression 1333 
 1334 
Type of Study Agent/Medication Design Effect on AAA 











Elastase/rat(142) Decreased development 
and size 
    
    
    
Animal Doxycycline Elastase/rat(172) Decreased development 
  Elastase/rat(173) Decreased progression 
    
Human Doxycycline Prospective Limited effect on 
progression 
  Pilot(184) Decreased progression 
  RCT(188) Possibly increased 
progression 
 1335 
Ang II= angiotensin II; ApoE-/-= apolipoprotein E deficient: CaCl2= calcium chloride; RCT= 1336 
randomised control trial 1337 
 1338 
 1339 
 1340 
 1341 
 1342 
 1343 
